CAR-T細胞療法的市場至2030年的預測：按藥物類型、目標抗原、應用、最終用戶和地區的全球分析

根據 Stratistics MRC 的資料，2023年全球 CAR-T 細胞治療市場規模為 33 億美元，預計預測期內年複合成長率為 30.5%，到2030年將達到 218 億美元。

CAR-T細胞療法是嵌合體受體T細胞療法的縮寫，是用於治療某些類型癌症的突破性免疫療法。患者自身的 T 細胞（一種免疫細胞）經過基因改造，可在其表面表達嵌合體抗原受體（CAR）。這個過程通常首先從患者的血液中採集 T 細胞，這個過程稱為白血球分離術。然後，這些 T 細胞在實驗室中經過基因改造，在其表面表達稱為 CAR 的特定受體。這些受體目的是識別並結合通常存在於癌細胞表面的特定蛋白質。

根據世界癌症研究基金會發表的癌症資料，2020年將新增白血病病例474,519例、多發性骨髓瘤病例176,404例、淋巴瘤病例627,439例。

癌症盛行率增加

儘管 CAR-T 技術取得了令人鼓舞的進展，但癌症發生率的增加帶來了重大挑戰。人口老化、環境因素和生活方式的改變等因素促成了這一趨勢。隨著對有效癌症治療的需求不斷增加，解決這一不斷上升的盛行率已成為 CAR-T 療法領域的醫療保健提供者和研究人員的當務之急。因此，市場正經歷著癌症患者不斷增加的令人擔憂的趨勢。

核准的治療方法數量有限

在快速發展的 CAR-T 細胞治療領域，核准的治療方法有限。這些治療方法對某些類型的血癌（包括白血病和淋巴瘤）顯示出顯著療效。然而，由於高成本、製造流程複雜以及需要進一步研究以擴大適應症和改善安全性，市場仍相對受到限制。

技術進步

CAR-T 細胞療法的進步徹底改變癌症治療並提供個人化免疫療法解決方案。增強的製造技術，例如借用的病毒載體設計和自動化細胞處理系統，可簡化生產、提高可擴展性並降低成本。 CAR 構建體的標靶修飾可提高腫瘤特異性、減少脫靶效應並增強治療效果。

製造成本高

CAR-T 細胞市場面臨巨大的製造成本，這主要是由於製程複雜且集中。製造 CAR-T 細胞需要先進的細胞工程技術、廣泛的品管措施和專門的基礎設施。此外，治療的個人化性質也增加了成本，因為每種治療都是針對個別患者量身定做的。這些高昂的成本對 CAR-T 細胞療法的普及和可及性構成了挑戰，限制了其在更廣泛的患者群體中的使用。

COVID-19 的影響：

COVID-19 的爆發對 CAR-T 細胞治療市場產生了重大影響，擾亂了臨床試驗、生產和患者的使用。供應鏈中斷和醫院容量減少推遲治療並阻礙市場成長。此外，資源轉移和 COVID-19 治療的優先順序轉移人們對 CAR-T 療法開發和部署的注意力。儘管面臨挑戰，但從長遠來看，對免疫療法和創新療法的更多關注可能會推動市場復甦和成長。

Tisagenleucel 業務預計將在預測期內成為最大的業務

Tissagenleucel 業務預計將成為預測期內最大的業務。這種藥物目的是針對特定癌細胞，在某些類型的白血病和淋巴瘤患者中顯示出顯著的療效。它的核准標誌著免疫治療的一個重要里程碑，為已經用盡常規治療方法的患者帶來了新的希望。這項成功很快就使 Tisagenlecleucel 成為 CAR-T 細胞治療市場的中流砥柱，推動了該領域的進步和進一步研究。

預計淋巴瘤細分市場在預測期內年複合成長率最高

由於免疫療法的進步，預計淋巴瘤領域在預測期內將出現最高的年複合成長率。 CAR T 細胞療法修改患者自身的免疫細胞，以便更佳識別和攻擊癌細胞。這種個人化方法在各種淋巴瘤亞型中顯示出有希望的結果，特別是對傳統治療沒有反應的患者。由於進行的研究和臨床試驗，淋巴瘤治療市場預計將進一步成長。

佔有率最大的地區

預計北美在預測期內將佔據最大的市場佔有率。 CAR-T療法致力於個人化醫療，在白血病和淋巴瘤等多種癌症的治療中越來越受歡迎。該地區強大的醫療基礎設施，加上支持性的法律規範，促進市場擴張。此外，製藥公司和學術機構之間的合作加速這一前景廣闊的領域的創新，預示著光明的市場前景。

年複合成長率最高的地區：

預計亞太地區在預測期內年複合成長率最高。每個國家的癌症盛行率不斷上升，再加上人們所認知的提高和診斷技術的改進，日益擴大可能受益於 CAR T 細胞療法的患者數量。各國進行的CAR-T細胞治療臨床試驗數量也大幅增加。這些臨床試驗評估不同 CAR-T 療法在不同類型癌症中的安全性和有效性，有助於該地區該領域的進展。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

• 公司簡介
  • 其他市場參與者的綜合分析（最多3家公司）
  • 主要企業SWOT分析（最多3家公司）
• 區域細分
  • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
• 競爭基準化分析
  • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

• 概述
• 相關利益者
• 調查範圍
• 調查方法
  • 資料探勘
  • 資料分析
  • 資料檢驗
  • 研究途徑
• 調查來源
  • 主要調查來源
  • 二次調查來源
  • 先決條件

第3章 市場趨勢分析

• 促進因素
• 抑制因素
• 機會
• 威脅
• 應用分析
• 最終用戶分析
• 新興市場
• 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

• 供應商的議價能力
• 買方議價能力
• 替代品的威脅
• 新進入者的威脅
• 競爭公司之間的敵對關係

第5章 全球CAR-T細胞治療市場：依藥物類型

• Brexucabtagene Autoleucel
• Axicabtagene Ciloleucel
• Tisagenlecleucel
• 其他類型的藥物

第6章 全球CAR-T細胞治療市場：依目標抗原

• CD19
• B細胞成熟抗原（BCMA）
• GD2
• CD20
• 其他標靶抗原

第7章 全球 CAR-T 細胞治療市場：依應用分類

• 急性淋巴性白血病
• 淋巴瘤
• 慢性淋巴性白血病
• 濾泡性淋巴瘤
• 肝細胞癌
• 大腸直腸癌
• 其他用途

第8章 全球 CAR-T 細胞治療市場：依最終使用者分類

• 癌症治療中心
• 醫院
• 其他最終用戶

第9章 全球CAR-T細胞治療市場：依地區

• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙
  • 其他歐洲國家
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 紐西蘭
  • 韓國
  • 其他亞太地區
• 南美洲
  • 阿根廷
  • 巴西
  • 智利
  • 南美洲其他地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 卡達
  • 南非
  • 其他中東和非洲

第10章 主要進展

• 合約、夥伴關係、協作和合資企業
• 收購和合併
• 新產品發布
• 業務擴展
• 其他關鍵策略

第11章 公司簡介

• Gilead Sciences Inc.
• Bristol-Myers Squibb
• Novartis AG
• Cartesian Therapeutics Inc.
• Merck & Co. Inc.
• Intellia Therapeutics
• Juno Therapeutics Inc.
• Bluebird Bio Inc.
• Sorrento Therapeutics Inc.
• Autolus Therapeutics
• Caribou Biosciences Inc.
• Miltenyi Biotech
• Celgene Corporation
• Aurora Biopharma Inc.
• Pfizer, Inc.

According to Stratistics MRC, the Global CAR-T Cell Therapy Market is accounted for $3.3 billion in 2023 and is expected to reach $21.8 billion by 2030 growing at a CAGR of 30.5% during the forecast period. CAR-T cell therapy, short for chimeric antigen receptor T-cell therapy, is a groundbreaking form of immunotherapy used in the treatment of certain types of cancer. It involves genetically modifying a patient's own T cells (a type of immune cell) to express chimeric antigen receptors (CARs) on their surface. The process typically starts by collecting T cells from the patient's blood through a process called leukapheresis. These T cells are then genetically engineered in a laboratory to express specific receptors called CARs on their surface. These receptors are designed to recognize and bind to specific proteins, typically found on the surface of cancer cells.

According to the cancer data published by World Cancer Research Fund International, there were 474,519 new cases of leukemia, 176,404 new cases of multiple myeloma and 627,439 new cases of lymphoma worldwide in 2020.

Market Dynamics:

Driver:

Increasing prevalence of cancer

Despite the promising advancements in CAR-T technology, the rise in cancer incidence poses significant challenges. Factors such as aging populations, environmental factors, and lifestyle changes contribute to this trend. As the demand for effective cancer treatments grows, addressing this rising prevalence becomes imperative for healthcare providers and researchers in the field of CAR-T therapy. Thus, the market is experiencing a concerning trend with an increasing prevalence of cancer cases.

Restraint:

Limited number of approved therapies

In the rapidly evolving field of CAR-T cell therapy, only a limited number of treatments have gained approval. These therapies have shown remarkable efficacy in treating certain types of blood cancers, including leukemia and lymphoma. However, the market remains relatively constrained due to high costs, complex manufacturing processes, and the need for further research to expand indications and improve safety profiles.

Opportunity:

Advancements in technology

Advancements in CAR-T cell therapy have revolutionized cancer treatment, offering personalized immunotherapy solutions. Enhanced manufacturing techniques, such as lent viral vector design and automated cell processing systems, streamline production, improving scalability and reducing costs. Targeted modifications to CAR constructs enhance tumour specificity and reduce off-target effects, boosting therapeutic efficacy.

Threat:

High manufacturing costs

The market faces significant manufacturing costs, primarily due to the complex and labor-intensive process involved. Manufacturing CAR-T cells requires sophisticated cell engineering techniques, extensive quality control measures, and specialized infrastructure. Additionally, personalized nature of the therapy adds to the expenses, as each treatment is tailored to individual patients. These high costs pose challenges for widespread adoption and accessibility of CAR-T cell therapy, limiting its availability to a broader patient population.

Covid-19 Impact:

The COVID-19 pandemic has significantly impacted the CAR-T cell therapy market, causing disruptions in clinical trials, manufacturing, and patient access. Supply chain disruptions and reduced hospital capacity have delayed treatments and hindered market growth. Additionally, diverted resources and prioritization of COVID-19 care have diverted attention from CAR-T therapy development and deployment. Despite challenges, increased focus on immunotherapy and innovative treatments may drive market recovery and growth in the long term.

The tisagenlecleucel segment is expected to be the largest during the forecast period

The tisagenlecleucel segment is expected to be the largest during the forecast period. Engineered to target specific cancer cells, it has shown remarkable efficacy in patients with certain types of leukemia and lymphoma. Its approval marked a significant milestone in immunotherapy, offering new hope for patients who have exhausted conventional treatments. With its success, Tisagenlecleucel has quickly become a pivotal player in the CAR-T cell therapy market, driving advancements and further research in the field.

The lymphoma segment is expected to have the highest CAGR during the forecast period

The lymphoma segment is expected to have the highest CAGR during the forecast period driven by advancements in immunotherapy. CAR-T cell therapy involves modifying a patient's own immune cells to better recognize and attack cancer cells. This personalized approach has shown promising results in various lymphoma subtypes, particularly in patients who have not responded to conventional treatments. With ongoing research and clinical trials, the market for therapy in lymphoma is poised for further growth.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. With a focus on personalized medicine, CAR-T therapies are gaining traction for treating various types of cancers, including leukemia and lymphoma. The region's robust healthcare infrastructure, coupled with supportive regulatory frameworks, fosters market expansion. Moreover, collaborations between pharmaceutical companies and academic institutions contribute to accelerating innovation in this promising field, promising a bright outlook for the market.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The rising prevalence of cancer in countries, coupled with growing awareness and improved diagnosis, was creating a larger pool of patients who could potentially benefit from CAR-T cell therapy. There was a significant increase in the number of clinical trials for CAR-T cell therapies being conducted in countries. These trials were evaluating the safety and efficacy of various CAR-T treatments across different types of cancer, contributing to the advancement of the field in the region.

Key players in the market

Some of the key players in CAR-T Cell Therapy market include Gilead Sciences Inc., Bristol-Myers Squibb, Novartis AG, Cartesian Therapeutics Inc., Merck & Co. Inc., Intellia Therapeutics, Juno Therapeutics Inc., Bluebird Bio Inc., Sorrento Therapeutics Inc., Autolus Therapeutics, Caribou Biosciences Inc., Miltenyi Biotech, Celgene Corporation, Aurora Biopharma Inc. and Pfizer, Inc.

Key Developments:

In December 2023, Bristol-Myers Squibb announced that it received manufacturing and marketing approval of the supplemental New Drug Application for an additional indication for Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy.

In May 2023, Autolus Therapeutics plc announced that the abstract for the pivotal Phase 2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) has been selected for an oral presentation at the European Hematology Association (EHA) 2023 Congress.

Drug Types Covered:

• Brexucabtagene Autoleucel
• Axicabtagene Ciloleucel
• Tisagenlecleucel
• Other Drug Types

Target Antigens Covered:

• CD19
• B-Cell Maturation Antigen (BCMA)
• GD2
• CD20
• Other Target Antigens

Applications Covered:

• Acute Lymphocytic Leukemia
• Lymphoma
• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Hepatocellular Carcinoma
• Colorectal Cancer
• Other Applications

End Users Covered:

• Cancer Treatment Centers
• Hospitals
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global CAR T-Cell Therapy Market, By Drug Type

• 5.1 Introduction
• 5.2 Brexucabtagene Autoleucel
• 5.3 Axicabtagene Ciloleucel
• 5.4 Tisagenlecleucel
• 5.5 Other Drug Types

6 Global CAR T-Cell Therapy Market, By Target Antigen

• 6.1 Introduction
• 6.2 CD19
• 6.3 B-Cell Maturation Antigen (BCMA)
• 6.4 GD2
• 6.5 CD20
• 6.6 Other Target Antigens

7 Global CAR T-Cell Therapy Market, By Application

• 7.1 Introduction
• 7.2 Acute Lymphocytic Leukemia
• 7.3 Lymphoma
• 7.4 Chronic Lymphocytic Leukemia
• 7.5 Follicular Lymphoma
• 7.6 Hepatocellular Carcinoma
• 7.7 Colorectal Cancer
• 7.8 Other Applications

8 Global CAR T-Cell Therapy Market, By End User

• 8.1 Introduction
• 8.2 Cancer Treatment Centers
• 8.3 Hospitals
• 8.4 Other End Users

9 Global CAR T-Cell Therapy Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Gilead Sciences Inc.
• 11.2 Bristol-Myers Squibb
• 11.3 Novartis AG
• 11.4 Cartesian Therapeutics Inc.
• 11.5 Merck & Co. Inc.
• 11.6 Intellia Therapeutics
• 11.7 Juno Therapeutics Inc.
• 11.8 Bluebird Bio Inc.
• 11.9 Sorrento Therapeutics Inc.
• 11.10 Autolus Therapeutics
• 11.11 Caribou Biosciences Inc.
• 11.12 Miltenyi Biotech
• 11.13 Celgene Corporation
• 11.14 Aurora Biopharma Inc.
• 11.15 Pfizer, Inc.

List of Tables

• Table 1 Global CAR T-Cell Therapy Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 3 Global CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
• Table 4 Global CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
• Table 5 Global CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
• Table 6 Global CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 7 Global CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
• Table 8 Global CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
• Table 9 Global CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
• Table 10 Global CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
• Table 11 Global CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
• Table 12 Global CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
• Table 13 Global CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
• Table 14 Global CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
• Table 15 Global CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
• Table 16 Global CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
• Table 17 Global CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
• Table 18 Global CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
• Table 19 Global CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 20 Global CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 21 Global CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
• Table 22 Global CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
• Table 23 Global CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 24 Global CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 25 North America CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
• Table 26 North America CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 27 North America CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
• Table 28 North America CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
• Table 29 North America CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
• Table 30 North America CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 31 North America CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
• Table 32 North America CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
• Table 33 North America CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
• Table 34 North America CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
• Table 35 North America CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
• Table 36 North America CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
• Table 37 North America CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
• Table 38 North America CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
• Table 39 North America CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
• Table 40 North America CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
• Table 41 North America CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
• Table 42 North America CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
• Table 43 North America CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 44 North America CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 45 North America CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
• Table 46 North America CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
• Table 47 North America CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 48 North America CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 49 Europe CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
• Table 50 Europe CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 51 Europe CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
• Table 52 Europe CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
• Table 53 Europe CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
• Table 54 Europe CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 55 Europe CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
• Table 56 Europe CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
• Table 57 Europe CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
• Table 58 Europe CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
• Table 59 Europe CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
• Table 60 Europe CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
• Table 61 Europe CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
• Table 62 Europe CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
• Table 63 Europe CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
• Table 64 Europe CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
• Table 65 Europe CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
• Table 66 Europe CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
• Table 67 Europe CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 68 Europe CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 69 Europe CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
• Table 70 Europe CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
• Table 71 Europe CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 72 Europe CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 73 Asia Pacific CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
• Table 74 Asia Pacific CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 75 Asia Pacific CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
• Table 76 Asia Pacific CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
• Table 77 Asia Pacific CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
• Table 78 Asia Pacific CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 79 Asia Pacific CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
• Table 80 Asia Pacific CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
• Table 81 Asia Pacific CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
• Table 82 Asia Pacific CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
• Table 83 Asia Pacific CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
• Table 84 Asia Pacific CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
• Table 85 Asia Pacific CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
• Table 86 Asia Pacific CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
• Table 87 Asia Pacific CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
• Table 88 Asia Pacific CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
• Table 89 Asia Pacific CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
• Table 90 Asia Pacific CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
• Table 91 Asia Pacific CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 92 Asia Pacific CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 93 Asia Pacific CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
• Table 94 Asia Pacific CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
• Table 95 Asia Pacific CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 96 Asia Pacific CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 97 South America CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
• Table 98 South America CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 99 South America CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
• Table 100 South America CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
• Table 101 South America CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
• Table 102 South America CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 103 South America CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
• Table 104 South America CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
• Table 105 South America CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
• Table 106 South America CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
• Table 107 South America CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
• Table 108 South America CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
• Table 109 South America CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
• Table 110 South America CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
• Table 111 South America CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
• Table 112 South America CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
• Table 113 South America CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
• Table 114 South America CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
• Table 115 South America CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 116 South America CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 117 South America CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
• Table 118 South America CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
• Table 119 South America CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 120 South America CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 121 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
• Table 122 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 123 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
• Table 124 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
• Table 125 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
• Table 126 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 127 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
• Table 128 Middle East & Africa CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
• Table 129 Middle East & Africa CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
• Table 130 Middle East & Africa CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
• Table 131 Middle East & Africa CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
• Table 132 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
• Table 133 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
• Table 134 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
• Table 135 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
• Table 136 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
• Table 137 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
• Table 138 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
• Table 139 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 140 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 141 Middle East & Africa CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
• Table 142 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
• Table 143 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 144 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)